Two-year-old Zorawar has a rare genetic disorder called aromatic L-amino acid decarboxylase deficiency and the treatment is not approved in Canada
Published Nov 14, 2026 • 3 minute read

See more Toronto Sun on Google — save as a Preferred Source
Advertisement 2
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Unlimited online access to articles from across Canada with one account.
- Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on.
- Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
- Support local journalists and the next generation of journalists.
- Daily puzzles including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Unlimited online access to articles from across Canada with one account.
- Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on.
- Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
- Support local journalists and the next generation of journalists.
- Daily puzzles including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Article content
A Brampton man is appealing to the public for help funding an expensive gene therapy treatment that may save his young son’s life.
Article content
Article content
“To us, Zorawar, is not just a child living with a rare genetic disorder,” father Mandeep Chandi said on the GoFundMe page set up for the two-year-old. “He is our beautiful little boy, our happiness, and a precious part of our family.”
Zorawar was diagnosed with a rare genetic disorder called Aromatic L-amino Acid Decarboxylase (AADC) deficiency.
AADC is an inherited disorder that affects the way nerve cells transmit information to other cells. Signs and symptoms usually make themselves known in the first six months of life. Affected infants may have feeding problems, weak muscle tone and sleep disturbances. Other signs and symptoms can include developmental delays and intellectual disabilities.
Life expectancy for children with severe AADC is estimated at five to seven years. Individuals with milder forms of the disease can reach adulthood.
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Advertisement 3
Article content
“All we want is to give him every possible opportunity to live a healthier, happier life,” Chandi said.

Falling on deaf ears
The family has approached individuals within the medical community and various levels of bureaucracy for funding, all to no avail.
“We have provided medical information, asked for guidance, and continued pursuing every possible avenue,” Chandi said, “Despite our efforts, we are still searching for a way forward.”
The way forward may be a trip to the United States for a gene therapy medicine called Kebildi. The treatment is not approved in Canada.
In November 2024, the U.S. Food and Drug Administration approved Kebildi. The one-time therapy costs approximately $3.95 million US. With out-of-pocket expenses, such as specialized inpatient surgical care and follow-up, the total cost can exceed $5.5 million.
The treatment is delivered by infusion into a precise region of the brain through a small hole in the skull during neurosurgery.
Advertisement 4
Article content
“While treatment requires specialist assessment and results cannot be guaranteed, we are fighting for Zorawar to have the opportunity to be evaluated for this therapy and receive it if he is eligible,” Chandi said.

Promising results
There are positive reports following the surgery.
“Results reported so far are based on 13 patients, ages 16 months to 10 years (average, 2.8 years), of whom 12 had severe AADC deficiency,” a report from Boston Children’s Hospital stated. “After 48 weeks of follow-up, three-quarters of the treated patients had achieved new gross motor milestones, including full head control, sitting with or without assistance, and walking.”
According to 2025 numbers from Fierce Pharmacy, Kebilidi is the second most expensive medicine in the U.S. The most expensive is Lenmeldy, priced at $4.25 million US, which is one-time, custom-made gene therapy used to treat early-onset metachromatic leukodystrophy (MLD) in children.
Advertisement 5
Article content
Read More
-
Doctors flagged for working too much could have chilling effect: OMA
-
Ontario pledges to connect everyone with a family doctor by 2029
-
OPINION: Ontario’s health-care wait times are ‘remarkably’ long
As a rare genetic disorder, there is no reliable data on the number of people affected globally by AADC. PTC Therapeutics, the Texas-based company that developed the therapy, estimates the number at 5,000.
As of Saturday afternoon, nearly $2 million had been raised on the GoFundMe, with more than 35 thousand donations given. The campaign aims to raise $5.5 million.
“His smile means everything to us,” Chandi said. “Every moment we spend with him is a memory we treasure.”
Article content
.png)
4 days ago
14


















Bengali (BD) ·
English (US) ·